stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) P/S ratio
As of 6 November 2026, Fortrea Holdings Inc. (FTRE) trades at a P/S ratio of 0.8×. Over the past ten years it has ranged from 0.0× (June 2023) to 1.3× (April 2024); the current reading is higher than 69% of that period. That is below the Biotechnology industry median of 9.4× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 0.6× | (6.67%) |
| FY2024 | 0.6× | (42.50%) |
| FY2023 | 1.1× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 0.7× | 16.05% |
| Jun 2026 | 0.6× | 89.34% |
| Mar 2026 | 0.3× | (43.66%) |
| Dec 2025 | 0.6× | 107.66% |
| 13 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. | 0.8× |
| SRPT Sarepta Therapeutics, Inc. compare | 1.0× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 2.0× |
| BHVN Biohaven Ltd. compare | 2.2× |
| VIR Vir Biotechnology, Inc. compare | 6.8× |
| ZYME Zymeworks Inc. compare | 58.0× |
| IMNM Immunome, Inc. compare | 168× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)